Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Publication of the KidneyIntelX one-year outcomes data likely this year should have positive impact on sales |
| We believe that we have identified the best path forward for having the greatest impact on clinical care and have -- and patient outcomes and doing it in a way that is very efficient for health systems and clinicians |
| I've been very fortunate to have built a leading diagnostic sales and marketing teams that have made innovative products widely used and standard of care |
| My experience in the field convinced me to cut my retirement short and jump in to spearhead a significant opportunity for growth and positively impact patients |
| Our marketing materials are already quite good, but we are using the FDA launch opportunity to improve messaging to further reflect the unique advantages of KidneyIntelX Technology and identifying patients at risk for kidney failure early on |
| Third, we are optimistic that short-term events in fiscal 2024 can help Spur testing growth |
| And so we're very excited about it |
| We will continue to hone on it over time, but I think we've made some tremendous strides |
| Our experience with the FDA De Novo pathway in achieving broad-scale reimbursement and Artificial Intelligence-enabled blood biomarker diagnostics should prove especially valuable in commercial efforts here |
| Following FDA De Novo Marketing Authorization, June 29, draft guidelines inclusion, comprehensive reimbursement and proven published performance to improve diabetes kidney and kidney health, KidneyIntelX is in a unique position to change preventative medicine in these very large and costly population health menus |
| Overall, testing volume remained steady with total tests of 1,297 and of which 56% were billable, which is a slightly higher total test volume than in both the prior quarter as well as the prior year fiscal first quarter |
| And equally as important, we'd like to see growing evidence of commercial traction in multiple areas |
| We've already seen obviously the preview of this, and we're very pleased with the fact that KidneyIntelX appears to be performing very similar to the real-world evidence program, which is completely independent in a different area of the country in a different system is Mount Sinai |
| And then it is very nice to see First Coast come on |
| Recent news highlighting potential breakthrough performance against diabetes and kidney disease, including the early stoppage of the Novo Nordisk, flow trial for their GLP-1 therapeutic Ozempic, signal a new era in kidney disease preventative medicine |
| More recently, we have taken a sharper knife to operating costs and implemented a plan to reduce payroll expense by over 35% year-over-year and total SG&A by more than 30% year-over-year, all while preserving the sales capacity to demonstrate revenue growth in the quarters ahead |
| But we're very excited about Atrium Wake Forest |
| It is a significant system and having the data that's been generated internally, we think that gives us and the clinicians, a lot of experience to move forward with Epic on a broad basis in calendar 2024 |
| Our focus is on expanding coverage contracts in these regions, building on our successes, including EmblemHealth, Blue Cross Blue Shield, Illinois and Blue Cross Blue Shield of Texas |
| And obviously, this real-world evidence is going to help in terms of generating adoption with clinicians |
| And let's see how it goes through the remainder of the year, but I'm optimistic that we get there |
| And while it's difficult for those employees affected, it is the right thing to do given the current environment and the opportunity to maximize resources against our sales efforts |
| That's great |
| CMI developed the innovative Bloodhound Hematology System for accurate diagnosis of blood-related diseases |
| So right now, with a reduced cost structure, with market conditions the way they are, the critical objective for the remainder of fiscal 2024 is to demonstrate commercial proof of concept in all of the key markets that we have targeted |
| It takes a long time to get this done, but we've done all of the fundamental work leading into calendar 2024 to make sure that we do have an extensive risk assessment program throughout the Atrium Wake Forest System to benefit patients in needs |
| And what I've been really impressed with is how quickly the clinicians get our message and why it's important and what KidneyIntelX can do for them, but their eyes kind of glaze over when you start talking about, these are the patients that we need you to find |
| We're also able to offer generous patient assistance program to patients who meet specified financial criteria |
| Given lousy sector market conditions in the early stage of our commercial rollout, we have been proactively organizing the company to last long-term, while we leverage our proprietary technology to unlock value |
| And the other good news is that we spent the last couple of years with the leading clinicians at Atrium Wake Forest using KidneyIntelX in an IRB controlled real-world evidence program |
| Statement |
|---|
| But again, very difficult market, concentration on really going after the cost basis has been helpful |
| It's been a challenge at the clinician level to identify patients that meet our criteria |
| Most importantly, having -- most importantly though, having watched two family members suffer through dialysis treatment with one ultimately getting a new kidney, I have seen the bad and the really bad in this space |
| It's a very, very difficult market, as you know and as everybody knows |
| So that, to me, was one of the biggest hurdles in the past |
| But more importantly, that have extinguished themselves within their organizations as prior Key club winners, top producers at whatever category that they were challenged with |
| However, diagnostic tests that were facing challenges at the local level or diagnostic tests that had a national Medicare -- had national Medicare policy implications that they could be considered at a national level |
| That to me is our, I think, our number one challenge |
| This was down from a net loss of about $12 million or $0.16 per share for the first quarter of fiscal '23, which included a foreign currency gain of $1.7 million |
| And they -- and why, because of the -- what we felt was a very slow movement forward with NGS |
| And I think the challenge for a lot of the other general algorithms, which are being used on large data sets, how do you get them validated? Ultimately, I believe they're going to have to run through FDA and that's going to be highly challenging |
| And that obviously impacted -- some of these tests are moving up on reimbursement |
| The -- just doing the math on the pricing of billable tests, you get a number significantly below the $950 per test |
| Operating expenses for the first quarter were $8.8 million on a GAAP basis, significantly reduced from the $12 million for the prior year period |
| Firstly, on the Clin-Risk model, which also made some headlines during Kidney Week, and as also mentioned alongside KidneyIntelX in the draft KDIGO guidelines, could you provide any more color on this? Does Clin-Risk represents a competitive threat to KidneyIntelX at all, and if not, why not? And secondly, on the planned cost reductions, just to make sure that I understand it correctly |
| During the LCD review process, NGS suspended claims payment |
| One thing that is abundantly clear, particularly since spending time with James and the Renalytix team at the American Society of Nephrology Kidney Week earlier this month, the kidney space is undergoing a wave of innovation and a shift towards preventative medicine |
| We're not going to forecast, but I am optimistic about 2024, now we need to prove it |
| While this does not happen often, we hope to avoid office and patient dissatisfaction with this policy |
Please consider a small donation if you think this website provides you with relevant information